Advertisement

Advertisement

CYDY Stock Latest News

CytoDyn Highlights Encouraging Early Leronlimab Colorectal Cancer Data

Company AnnouncementsCytoDyn Highlights Encouraging Early Leronlimab Colorectal Cancer Data

CytoDyn Extends Convertible Debt Maturities, Lowers Interest Costs

PremiumCompany Announcements

CytoDyn Extends Convertible Debt Maturities, Lowers Interest Costs

2M ago

CytoDyn Boosts Liquidity Through Significant Unregistered Equity Sales

PremiumCompany Announcements

CytoDyn Boosts Liquidity Through Significant Unregistered Equity Sales

3M ago

CytoDyn closes $17.5M financing for leronlimab development

PremiumThe Fly

CytoDyn closes $17.5M financing for leronlimab development

3M ago

CytoDyn announces new data on leronlimab’s treatment of mTNBC

PremiumThe Fly

CytoDyn announces new data on leronlimab’s treatment of mTNBC

3M ago

CytoDyn announces benefactor committed funding to support EAP

PremiumThe FlyCytoDyn announces benefactor committed funding to support EAP

4M ago

CytoDyn releases 2025 December letter to shareholders

The Fly

CytoDyn releases 2025 December letter to shareholders

6M ago

CytoDyn announces findings on PD-L1 survival in triple-negative breast cancer

The Fly

CytoDyn announces findings on PD-L1 survival in triple-negative breast cancer

6M ago

CytoDyn Reaches Settlement in Securities Lawsuit

PremiumCompany Announcements

CytoDyn Reaches Settlement in Securities Lawsuit

6M ago

CytoDyn announces resolution of class action lawsuit

PremiumThe Fly

CytoDyn announces resolution of class action lawsuit

6M ago

CytoDyn Approves Share Increase at Annual Meeting

PremiumCompany Announcements

CytoDyn Approves Share Increase at Annual Meeting

6M ago

CytoDyn Secures $30 Million Funding Commitment

PremiumCompany Announcements

CytoDyn Secures $30 Million Funding Commitment

7M ago

CytoDyn secures $30M commitment from Yorkville Advisors

PremiumThe FlyCytoDyn secures $30M commitment from Yorkville Advisors

7M ago

CytoDyn’s Phase 2 Study: A Potential Breakthrough in mCRC Treatment

Company Announcements

CytoDyn’s Phase 2 Study: A Potential Breakthrough in mCRC Treatment

7M ago

CytoDyn CEO says moving with ‘discipline and urgency’ along ‘well-defined’ path

The Fly

CytoDyn CEO says moving with ‘discipline and urgency’ along ‘well-defined’ path

8M ago

CytoDyn to present poster at AACR conference on mTNBC

PremiumThe Fly

CytoDyn to present poster at AACR conference on mTNBC

8M ago

CytoDyn files $100M mixed securities shelf

PremiumThe Fly

CytoDyn files $100M mixed securities shelf

10M ago

CytoDyn announces survival data in patients with mCRC treated with leronlimab

PremiumThe Fly

CytoDyn announces survival data in patients with mCRC treated with leronlimab

11M ago

CytoDyn announces first patient dosed in Phase II oncology trial

PremiumThe Fly

CytoDyn announces first patient dosed in Phase II oncology trial

11M ago

CytoDyn announces data on mechanism of action of leronlimab

PremiumThe FlyCytoDyn announces data on mechanism of action of leronlimab

1y ago

CytoDyn Appoints Robert Hoffman as New CFO

Company Announcements

CytoDyn Appoints Robert Hoffman as New CFO

1y ago

CytoDyn appoints Robert Hoffman as CFO

The Fly

CytoDyn appoints Robert Hoffman as CFO

1y ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >